Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Eli Lilly Lifts Its 2026 Sales Forecast by $5.5 Billion at the Midpoint as Mounjaro Jumps 65%, Even as Its New Obesity Pill Misses Estimates

by Team Lumida
October 29, 2026
in Equities
Reading Time: 3 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Lilly crushed estimates. Third-quarter adjusted EPS was $7.48 versus $6.26 expected and revenue was $24.40 billion versus $22.61 billion, and the shares rose about 9% Thursday.
  • The sales outlook jumped. Lilly now expects 2026 revenue of $91 billion to $92 billion, up from $85 billion to $87 billion, a $5.5 billion increase at the midpoint (Lumida calculation). Its adjusted EPS outlook moved to $35 to $36 from $35.50 to $36.50 because a $4.07 underlying raise was offset by $4.57 a share of deal charges.
  • The injectables did the heavy lifting. Mounjaro revenue rose 65% to $10.72 billion, beating the $10.10 billion StreetAccount estimate, with sales outside the US up 93%, while Zepbound grew 49% to $5.35 billion versus $5.09 billion expected.
  • The pill was the soft spot. Foundayo brought in $184 million against forecasts of around $229 million, though Lilly said US prescriptions and new patients doubled from the prior quarter and about 4 in 10 patients starting an oral obesity drug choose it.

What Happened?

Lilly reported Thursday morning, with US revenue up 34% to $15.1 billion on a 41% volume increase, partly offset by a 7% drop in realized prices driven mainly by Zepbound. Sales outside the US climbed 47% to $9.3 billion on a 76% surge in volume and a 29% decline in realized prices. Net income rose to $6.45 billion from $5.58 billion a year earlier, and the quarter included a $410 million sales-based milestone payment for Jardiance from its Boehringer Ingelheim collaboration.

Why It Matters?

Lilly is widening its lead over Novo Nordisk, holding 63% of the US obesity and diabetes drug market in the quarter versus Novo’s 36.6%, and 58.4% internationally versus 41.6%. Lower US prices after last year’s drug-pricing deal with the Trump administration are being outweighed by volume, helped by Medicare’s temporary pilot covering GLP-1s for weight loss since July. CEO Ricks estimated only 3% to 10% of eligible US patients access obesity care and said the “room for expansion here of this market is dramatic.” The S&P 500 health care sector hit an all-time high Thursday, up more than 2%, according to CNBC’s live coverage.

What’s Next?

Lilly expects Foundayo to win US approval for Type 2 diabetes in the fourth quarter, which could broaden the pill’s market as it competes with Novo’s oral drug launched in January. Investors will watch whether volume growth keeps outrunning price declines, and how Lilly deploys its profits after deals such as its agreement to buy Merida Biosciences.

Affected Tickers and Coins: LLY, NVO, XLV

Source: CNBC, CNBC

Previous Post

US Economy Grows 3.4%, Topping a 3% Pace for the First Time in a Year, as PCE Inflation Hits 3.6% and Traders Price an 83% Chance of a December Hike

Next Post

Merck Beats by 41 Cents and Raises Its Profit Outlook as Keytruda’s New Shot Hits a Record $830 Million Ahead of the 2028 Patent Cliff

Recommended For You

Costco’s US Comparable Sales May Grow More Than 10% in November as Tech Outages Spark Emergency Stockpiling, Mizuho Says, Raising Its Target to $1,150

by Team Lumida
9 hours ago

Mizuho said tech outages are driving panic buying at Costco, estimating late-October US comps ex-gas rose 11% to 12%, and lifted its target to $1,150.

Read more

Textron Sells Its Industrial Segment to Kingswood Capital for $1.2 Billion and Authorizes a 35 Million-Share Buyback to Focus on Aviation, Bell and Defense

by Team Lumida
9 hours ago

Textron agreed to sell its industrial unit for $1.2 billion, expects about $1.1 billion in net proceeds, and approved a new 35 million-share buyback.

Read more

Apple Trades at 37 Times Forward Earnings, Its Highest Since 2007, After a 30% Gain Makes It the Market’s AI Haven and a $5.1 Trillion Company

by Team Lumida
9 hours ago

Apple’s 30% gain this year has pushed it to 37 times forward earnings and a record PEG ratio, as investors pay up for a stock seen as an...

Read more

TJX Raises Its Full-Year EPS Outlook to $5.17-$5.20 After Comparable Sales Rise 4% and Sales Hit $16 Billion, Sending Shares Up 6.6% Premarket

by Team Lumida
9 hours ago

TJX raised its full-year profit outlook after Q3 sales rose 6% to $16 billion and comparable sales beat at 4%, sending the stock up 6.6% premarket.

Read more

Lowe’s Raises Its Sales Outlook to About $92.5 Billion as Online Sales Jump 17.4% and Comparable Sales Rise 1.8%, Yet Shares Slip More Than 3% Premarket

by Team Lumida
9 hours ago

Lowe’s lifted its full-year sales outlook to about $92.5 billion on 17.4% online growth and pro strength, though shares fell more than 3% premarket.

Read more

Jensen Huang and Commerce Secretary Lutnick Agree to Appear Before the Senate Banking Committee, as House Democrats Probe Cantor Fitzgerald’s Nvidia Holdings

by Team Lumida
9 hours ago

Tim Scott said Huang and Lutnick agreed to appear before Christmas, as House Democrats sought records on Cantor Fitzgerald’s Nvidia stake.

Read more

Anthropic Weighs Upsizing Its IPO and Pricing Well Above $80 as Orders Reach About $400 Billion From Institutions and Nearly $100 Billion From Retail, With Cboe Options as Soon as Monday

by Team Lumida
9 hours ago

Anthropic is weighing a bigger IPO priced well above $80 after about $400 billion of institutional orders, with Nasdaq trading as ANT set for Thursday.

Read more

Medline’s Backers Blackstone, Carlyle and Hellman & Friedman Raise $2.1 Billion Selling 60 Million Shares at $35.50, With a $200 Million Company Buyback, After the Stock Fell 3.8%

by Team Lumida
17 hours ago
Dow Ends the Week Down 2% for a Third Straight Loss While the Nasdaq Gains 0.3% and the 10-Year Returns to 5.00%

Medline holders including Blackstone and Carlyle raised $2.1 billion selling 60 million shares at $35.50; the company will buy back up to $200 million.

Read more

The SEC Is Investigating Nvidia Over Whether Its Disclosures Misled Investors, the Same Day It Reports $115.8 Billion in Revenue and Huang Says He Would Return as CEO if Asked

by Team Lumida
17 hours ago

WSJ reports the SEC is investigating Nvidia, including whether disclosures misled investors, as the company posts $115.8 billion in quarterly revenue.

Read more

Nvidia Posts $115.84 Billion Revenue and Guides to $130 Billion, Lifts Fiscal 2028 Growth Target to 75% and Adds $150 Billion to Buybacks, With Shares Up Almost 5% After Hours as the Board Rules Out Huang’s Return

by Team Lumida
17 hours ago

Nvidia beat on revenue, guided Q4 to $130 billion and raised its fiscal 2028 growth target to 75%, with shares up almost 5% after hours.

Read more
Next Post

Merck Beats by 41 Cents and Raises Its Profit Outlook as Keytruda’s New Shot Hits a Record $830 Million Ahead of the 2028 Patent Cliff

Caterpillar Slides 9% Despite a Beat and Fortinet Plunges 25%, While Crocs Surges 18% and Norwegian Cruise Jumps on Earnings

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Tron Settles Up to $190 Billion of Stablecoins a Week on 27 Validators, and the Bull Case Rests on One Issuer

Peirce Leaves the SEC With Two Commissioners Remaining and a New Rule Letting the Agency Operate With One

October 2, 2026
House Rebuke of Canada Tariffs Exposes Political Risk Around Trump’s Trade Agenda

$20.6 Billion in Tariff Refunds Are Headed Back to US Importers

May 27, 2026
September Rate Cut Likely as Job Market Risks Increase, Says Fed

Fed Official Signals Cautious Approach to Rate Cuts Amid Economic Uncertainty

January 10, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018